Physician profile
Jack M Chapman
NPI 1689662751
$243,541.07
in general payments reported to CMS, 2019-2025
35 companies · $40K in 2025
The $40K reported for 2025 was more than what 98% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $102K · 2020: $7,523 · 2021: $50K · 2022: $13K · 2023: $25K · 2024: $6,283 · 2025: $40K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $59K · Food and Beverage: $10K · Travel and Lodging: $1,261 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $700 · Education: $159 · Honoraria: $32.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $58,921.15 |
| Food and Beverage | $10,344.70 |
| Travel and Lodging | $1,260.51 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $700.00 |
| Education | $159.34 |
| Honoraria | $32.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $145,234.23 | 2019-2025 | Cequa |
| Lensar, INC. | $53,730.48 | 2023-2025 | Lensar Laser System |
| Alcon Vision LLC | $25,569.90 | 2019-2025 | Centurion, Wavelight Refractive Suite, Clareon |
| Bausch & Lomb Americas INC. | $4,940.97 | 2023-2025 | Envista Envy Iol, Envista Mx60 Iol, Miebo |
| Nordic Pharma, INC. | $3,375.45 | 2024-2025 | Lacrifill, Lacrifill |
| Tearlab Corp | $2,730.29 | 2022-2024 | Scoutpro Osmolarity System, Tearlab Osmolarity System |
| Biotissue Holdings INC. | $1,706.56 | 2024-2025 | |
| Rxsight INC | $946.55 | 2022-2025 | Rxsight Injector Handpiece, Rxsight Injector Cartridge, Rxsight Light Delivery Device (Ldd) |
| Eyevance Pharmaceuticals LLC | $561.17 | 2019-2020 | |
| Alcon Research LLC | $455.70 | 2023 | |
| Oyster Point Pharma, INC. | $423.47 | 2022-2025 | Tyrvaya, Ryzumvi |
| Dompe US, INC. | $399.48 | 2019-2025 | Oxervate |
| Allergan, INC. | $365.64 | 2019-2022 | |
| Rayner Intraocular Lenses Limited | $328.32 | 2024-2025 | Rayone Emv, Rayone Aspheric, Rayner Cataract Set 1 |
| Eyepoint US, INC. | $320.89 | 2019 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $301.35 | 2024-2025 | Xdemvy |
| Johnson & Johnson Surgical Vision, INC. | $242.58 | 2019-2025 | Tecnis Iol, Tecnis Simplicity, Veritas Vision System |
| Abbvie INC. | $211.78 | 2022-2025 | Alphagan P, Lumigan, Vuity |
| Sight Sciences, INC. | $194.13 | 2019-2024 | Omni Surgical System |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $189.60 | 2019-2021 | |
| New World Medical,INC. | $188.06 | 2023 | |
| Horizon Therapeutics Plc | $178.88 | 2021-2023 | Tepezza |
| Glaukos Corporation | $155.59 | 2020-2025 | Radius, Idosetr, Photrexa Viscous and Photrexa |
| Kala Pharmaceuticals, INC. | $114.61 | 2019-2022 | |
| Ocular Therapeutix, INC. | $112.86 | 2019-2023 | Dextenza |
| Mallinckrodt Hospital Products INC. | $94.20 | 2024-2025 | Acthar |
| Astellas Pharma US INC | $74.82 | 2025 | Izervay |
| Aerie Pharmaceuticals, INC. | $73.75 | 2019-2021 | |
| Amgen INC. | $61.70 | 2024-2025 | Tepezza |
| Harrow Eye, LLC | $58.32 | 2024-2025 | Vevye |
| Omeros Corporation | $56.62 | 2019 | |
| Carl Zeiss Meditec USA, INC. | $56.06 | 2021-2023 | Iolmaster 700 |
| Quidel Corporation | $54.39 | 2023 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Novartis Pharmaceuticals Corporation | $13.27 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Chapman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.